Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Galapagos, Servier Enter Strategic Alliance for Cancer Therapies

Oct. 3 (Bloomberg) -- Galapagos NV and Servier of France have entered a strategic alliance to develop new cancer therapies that could potentially result in as much as 260 million euros in milestone payments for Galapagos.

Galapagos will be responsible for the discovery and development of new candidate drugs against the companies’ combined oncology targets. Servier will have an exclusive option to license each small molecule program after the completion of pre-clinical development by Galapagos.

Link to Statement:{NSN LSH5Z43PR6RK <GO>}

Link to Company News:{GLPG BB <Equity> CN <GO>}

To contact the editor responsible for this story: Andrew Clapham at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.